Core Points - Shanghai Aopumai Biotechnology Co., Ltd. announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd., successfully passed the EU Qualified Person (QP) audit, receiving a compliance audit report [1][2] - The audit covered various aspects including quality management, production management, facilities, material systems, and packaging and labeling systems, confirming that Silun Biotechnology meets current EU GMP requirements [1] - This achievement establishes a solid foundation for the company's high-quality research and production services in the large molecule biopharmaceutical sector, facilitating further expansion into EU and international markets [2] Company Impact - The successful QP audit indicates that the quality management system of Silun Biotechnology has reached the standards required by EU GMP regulations [2] - The company has developed a comprehensive CDMO service platform for large molecule biopharmaceuticals, providing full-process support from early research to commercial production [1] - The passing of the QP audit is not expected to have a significant impact on the company's current performance [2]

Core Viewpoint - Aopu Mai (688293.SH) announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd. (referred to as "Silun Biotechnology"), successfully passed the EU Qualified Person (QP) audit, receiving a compliance audit report issued by the QP [1] Group 1 - The successful completion of the QP audit indicates that Silun Biotechnology's quality management system meets the EU GMP regulatory requirements [1] - This achievement ensures high-quality research and production services in the field of macromolecular biopharmaceuticals [1] - The accomplishment lays a solid foundation for the company to further expand into international markets, including the EU [1]

Core Viewpoint - The company, Aopumai (688293.SH), announced that its wholly-owned subsidiary, Shanghai Silun Biotechnology Co., Ltd. (referred to as "Silun Biotechnology"), successfully passed the Qualified Person (QP) audit by the European Union, receiving a compliance audit report [1] Group 1 - The successful completion of the QP audit indicates that Silun Biotechnology's quality management system meets the EU GMP regulatory requirements [1] - This achievement ensures high-quality research and production services in the field of macromolecular biopharmaceuticals [1] - The compliance lays a solid foundation for the company to further expand into international markets, including the EU [1]